Efficacy—pembrolizumab monotherapy versus chemotherapy
death
CPS
In the PD-L1 CPS ≥1 population, median OS was 22.7 months (95% CI, 14.3–28.5) with pembrolizumab versus 13.8 months (95% CI, 10.5–16.9) with chemotherapy (HR, 0.54; 95% CI, 0.35–0.82) (Kaplan–Meier estimates of overall survival for patients enrolled in Asia in the KEYNOTE-062 study. Pembrolizumab monotherapy versus chemotherapy in the (A) programmed death ligand 1 (PD-L1) combined positive score (CPS) ≥1 population and the (B) PD-L1 CPS ≥10 population. Pembrolizumab plus chemotherapy versus chemotherapy in the (C) PD-L1 CPS ≥1 population and the (D) PD-L1 CPS ≥10 population. HR, hazard ratio and NE, not estimable.In the PD-L1 CPS ≥1 population, median PFS was 4.1 months (95% CI, 2.2–7.2) with pembrolizumab versus 6.5 months (95% CI, 4.2–7.1) with chemotherapy (HR, 1.11; 95% CI, 0.76–1.64) (Kaplan–Meier estimates of progression-free survival for patients enrolled in Asia in the KEYNOTE-062 study. Pembrolizumab monotherapy versus chemotherapy in the (A) PD-L1 CPS ≥1 population and the (B) PD-L1 CPS ≥10 population. Pembrolizumab plus chemotherapy versus chemotherapy in the (C) PD-L1 CPS ≥1 population and the (D) PD-L1 CPS ≥10 population.In the PD-L1 CPS ≥1 population, 14 of 62 patients (22.6%) who received pembrolizumab versus 23 of 61 (37.7%) who received chemotherapy had an objective response, with complete responses in 4 of 62 patients (6.5%) versus 3 of 61 (4.9%), respectively (Response summary for patients enrolled in Asia in the KEYNOTE-062 study by PD-L1 CPS cut-off